Schwab Charles Investment Management Inc. lifted its position in Exelixis, Inc. (NASDAQ:EXEL) by 0.2% in the 4th quarter, HoldingsChannel reports. The fund owned 1,022,928 shares of the biotechnology company’s stock after acquiring an additional 2,449 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Exelixis were worth $31,098,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Mark Sheptoff Financial Planning LLC bought a new position in shares of Exelixis in the 3rd quarter worth approximately $120,000. Fisher Asset Management LLC bought a new position in shares of Exelixis in the 3rd quarter worth approximately $213,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Exelixis in the 3rd quarter worth approximately $236,000. CIBC Asset Management Inc bought a new position in shares of Exelixis in the 3rd quarter worth approximately $238,000. Finally, Crossmark Global Holdings Inc. bought a new position in shares of Exelixis in the 3rd quarter worth approximately $239,000. 81.43% of the stock is owned by hedge funds and other institutional investors.

Shares of Exelixis, Inc. (EXEL) opened at $29.05 on Tuesday. The firm has a market capitalization of $8,346.02, a P/E ratio of 59.29, a P/E/G ratio of 0.79 and a beta of 1.84. Exelixis, Inc. has a 52 week low of $18.03 and a 52 week high of $32.50.

EXEL has been the subject of several research reports. BidaskClub raised Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 target price for the company in a research report on Tuesday, January 2nd. TheStreet raised Exelixis from a “c+” rating to a “b-” rating in a research report on Wednesday, October 18th. Piper Jaffray Companies reissued an “overweight” rating on shares of Exelixis in a research report on Monday, October 16th. Finally, SunTrust Banks reissued a “buy” rating and issued a $38.00 target price on shares of Exelixis in a research report on Thursday, December 21st. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $32.13.

In related news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total value of $454,500.00. Following the sale, the director now owns 64,829 shares in the company, valued at approximately $1,964,318.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://theolympiareport.com/2018/02/13/schwab-charles-investment-management-inc-increases-stake-in-exelixis-inc-exel.html.

Exelixis Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.